wwwext.amgen.comOCT 12 min read$AMGN

EUROPEAN COMMISSION APPROVES LUMYKRAS® (SOTORASIB) FOR PATIENTS WITH KRAS G12C-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER| Amgen

Amgen's LUMYKRAS (sotorasib) received conditional EU approval for treating KRAS G12C-mutated advanced NSCLC. Approval based on Phase 2 trial showing 37.1% response rate. Amgen plans global expansion.

Original reporting

wwwext.amgen.com

Published Oct 1, 2026, 12:30 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Oct 1, 2026, 12:30 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

EUROPEAN COMMISSION APPROVES LUMYKRAS® (SOTORASIB) FOR PATIENTS WITH KRAS G12C-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER| Amgen — source image — Source · wwwext.amgen.com

Decision brief

The 30-second read

$AMGNBullishHigh

Why it matters

The approval could add significant revenue, especially as KRAS G12C is a prevalent mutation in NSCLC. Market may re‑price Amgen's oncology outlook.

Market read

Regulatory clearance for a first‑in‑class cancer drug is a high‑impact event for Amgen and the broader oncology sector.

What to watch

Potential post‑approval safety monitoring and requirement for confirmatory trials may limit immediate sales.

Relevance 1/10Novelty 9/10Timing: today

Background

Amgen announced EU conditional approval for its KRAS G12C inhibitor sotorasib, expanding its approved markets beyond the US.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$AMGNBullishHigh confidence

Context

European Commission granted conditional marketing authorization for Amgen's sotorasib (LUMYKRAS) for KRAS G12C NSCLC.

Expected impact

likely upward pressure as investors price in new EU revenue stream

Evidence & confidence

Regulatory clearance is a material catalyst for a large-cap biotech; market typically reacts positively to new indications.

Market effects

Sector

strengthens the oncology/targeted therapy sector, may boost peers with KRAS pipelines.

Regional

adds to European biotech pipeline credibility, could lift EU biotech indices.

Global

reinforces Amgen's global oncology franchise, may influence global biotech sentiment.

Counterpoint

What could challenge this read

If EU uptake is slow due to reimbursement hurdles, the price rally could be muted.

Key entities

company
Amgen
US biotech firm developing sotorasib.
regulator
European Commission
Granted conditional marketing authorization.

Read at source ← All news

OCT 1

$AMGNMed

Drugmakers Turn to Proteomics to Map How Medicines Work

Drugmakers are increasingly using proteomics to study protein-level pathways of drug effects. Amgen, AstraZeneca, Johnson & Johnson, and MSD are involved in a UK Biobank project. In Korea, Bertis' proteomics tech was used in Hanmi Pharmaceutical's obesity drug research. The global proteomics market is expected to grow to $97.7B by 2033, per Grand View Research.

en.sedaily.com2 min

OCT 1

$AMGNMedAI 9/10

Imdelltra extends survival in relapsed small cell lung cancer, Korean investigator says

Amgen's Imdelltra (tarlatamab) showed extended survival in relapsed small cell lung cancer. In the DeLLphi-304 trial, median overall survival was 13.6 months with tarlatamab vs. 8.3 months with chemotherapy. Professor Ahn Myung-ju of Hanyang University Medical Center presented the findings at an Amgen Korea press conference.

koreabiomed.com2 min

SEP 30

$AMGNMedAI 8/10

Is Amgen (AMGN) Undervalued Following Its Phase 3 Sjögren's Disease Trial Update?

Amgen (AMGN) reported positive Phase 3 trial data for its Sjögren's disease drug, dazodalibep, boosting its autoimmune pipeline. The stock has surged 17.2% in 90 days and 29.3% year-to-date. Analysts debate its valuation, with one model suggesting it's overvalued at $423.64 vs. a fair value of $359.98, while another DCF model estimates it's undervalued at $672.77.

simplywall.st3 min

SEP 30

$AMGNMedAI 9/10

Amgen reveals 6-point drop in lupus severity behind phase 2 win for Horizon antibody

Amgen's phase 2 trial of daxdilimab showed a 6-point reduction in lupus severity at the lower dose, meeting primary and secondary endpoints. The study involved 72 patients with discoid lupus. Amgen plans to advance daxdilimab into registrational development, acquired from Horizon Therapeutics in 2023. The drug previously failed in systemic lupus trials.

fiercebiotech.com2 min

SEP 29

$AMGNHighAI 9/10

Amgen (AMGN) Has a New Growth Opportunity. But How Much Is It Really Worth?

Amgen (AMGN) reported positive Phase 3 trial results for dazodalibep in systemic Sjögren’s disease, meeting primary endpoints. Citi reaffirmed a Neutral rating and $405 price target, citing unanswered questions about efficacy and competitive profile. Amgen's Q2 2026 revenue grew 10% YoY to $10.1B, with key growth drivers like TEZSPIRE and UPLIZNA. However, legacy products faced biosimilar erosion, with Prolia and XGEVA sales declining 32% and 34%, respectively.

insidermonkey.com2 min